Qiagen N.V. updates earnings calendar, shares tracked against diagnostics peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 07:11.

Qiagen N.V. (NL0012169213) has outlined its next financial reporting dates and investor events on its website, giving Nasdaq-focused investors better visibility on the diagnostics group’s upcoming communications. The company competes globally with peers such as Thermo Fisher Scientific and Abbott Laboratories in molecular testing.

What Qiagen discloses on timing

According to its investor relations calendar, Qiagen plans regular quarterly updates that typically cover revenue trends, adjusted earnings per share and cash flow development for its sample technologies and molecular diagnostics portfolio. The company usually combines results releases with conference calls aimed at analysts and institutional investors, often hosted out of the United States and Germany.Qiagen financial reports and calendar

Qiagen highlights in its materials that these reporting dates are aligned with Nasdaq requirements and European transparency rules, reflecting its dual focus on US and European investors. The releases typically include segment information for its Molecular Diagnostics and Life Sciences segments as well as commentary on regional trends in the Americas, EMEA and Asia-Pacific.

Analyst coverage and market positioning

Several international houses follow Qiagen stock on a regular basis, including Goldman Sachs, JPMorgan and Deutsche Bank, which publish updates on the company’s earnings power, free cash flow generation and valuation relative to health-care tools and diagnostics peers. Consensus data from financial portals show that most covering analysts focus on Qiagen’s recurring consumables revenue and instrument installed base as key drivers for medium-term growth.MarketScreener consensus overview for Qiagen

Investment research often benchmarks Qiagen against larger diagnostics and life-science tools groups such as Thermo Fisher Scientific and Abbott Laboratories, assessing relative valuation multiples like price-to-earnings and enterprise-value-to-EBITDA. For Nasdaq investors, Qiagen is typically classified within the health-care sector, tools and diagnostics subsegment, making it comparable with names like Illumina and Agilent Technologies in sector allocation strategies.

The product behind the stock

Qiagen generates most of its revenue with sample preparation kits, reagents and instruments used in molecular diagnostics and research. A prominent example is its QIAcube instrument line, which automates nucleic acid extraction workflows for laboratories handling clinical and research samples worldwide.

The listing in brief

Qiagen N.V. shares trade on Nasdaq under the ticker QGEN and on the Frankfurt Stock Exchange, with the primary listing generally considered to be on Nasdaq in US dollars; recent quotes place the stock in the mid-double-digit dollar range on a typical trading day.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.